Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
Recruiting · NCT06533761 · Registry updated 2026-08-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myelodysplastic syndrome, myeloid leukemia, neoplasm | Recruiting | Phase 1 | 2026-08-25 | NCT06533761 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Stelexis BioSciences | 2 |
12 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Anshutz Cancer Pavilion | Aurora | United States | 1 |
| City of Hope | Duarte | United States | 238 |
| Cleveland Clinic | Cleveland | United States | 21 |
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| Hospital San Pedro de Alcántara | Cáceres | Spain | 10 |
| Hospital Universitari i Politècnic La Fe | Valencia | Spain | 27 |
| MD Anderson Cancer Center | Houston | United States | 5 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| Moffitt Cancer Center | Tampa | United States | 523 |
| Montefiore Medical Center | New York | United States | 1 |
| Ohio State University | Columbus | United States | 169 |
| Washington University in St Louis | St Louis | United States | 6 |